LAUSR

It is now 1 year and 8 months since Molecular Oncology became fully Open Access in 2017 under the FEBS Press platform and Wiley. Interestingly, the number of submissions remained comparable during 2016 and 2017, and we are delighted to report that so far in 2018, submissions have almost doubled as compared to the same period last year. To tackle the increase in submissions, we recently appointed Section Editors in basic/preclinical research (Michael Boutros, Heidelberg, Germany; George Ca lin, Houston, USA; Gerry Melino, Cambridge, UK) and in clinical research (Mef Nilbert, Copenhagen, Denmark; Klaus Pantel, Hamburg, Germany). Their expertise and commitment will be essential to the future development of the Journal, and together with the Editor-in-Chief, they will apply the same rigorous standards of peer review to ensure that the journal keeps its high standing among cancer journals worldwide. In addition, we have strengthened the Editorial office by appointing Duncan Wright as Editorial Associate to coordinate editorial matters. Moreover, we have put into operation significant changes to the Web site to facilitate access to critical information. I want to take this opportunity to thank Jos e Moreira, with whom I started the Journal in 2007, for his instrumental and countless contributions to the development of the Journal, in particular during the more difficult early years. Jos e will remain at the Journal as Review Editor. I would also like to thank Dorte Holst Pedersen, our Editorial Assistant, for her valuable support, and Mary Purton, Coordinator of FEBS Press, for her continuous advice during the transition process. Finally, I would like to convey my sincere thanks to the readers for their continuing support and take this opportunity to invite you to submit your research articles to Molecular Oncology.